DE60316297D1 - Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten - Google Patents

Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten

Info

Publication number
DE60316297D1
DE60316297D1 DE60316297T DE60316297T DE60316297D1 DE 60316297 D1 DE60316297 D1 DE 60316297D1 DE 60316297 T DE60316297 T DE 60316297T DE 60316297 T DE60316297 T DE 60316297T DE 60316297 D1 DE60316297 D1 DE 60316297D1
Authority
DE
Germany
Prior art keywords
treatment
therapy
diseases
angiogener
compounds useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60316297T
Other languages
English (en)
Other versions
DE60316297T2 (de
Inventor
Jens Lichtenberg
Palle Christophersen
Bjarne H Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Application granted granted Critical
Publication of DE60316297D1 publication Critical patent/DE60316297D1/de
Publication of DE60316297T2 publication Critical patent/DE60316297T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60316297T 2002-08-01 2003-07-31 Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind Expired - Lifetime DE60316297T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK200201165 2002-08-01
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DK200201839 2002-11-28
DK200300371 2003-03-11
DKPA200300371 2003-03-11
PCT/DK2003/000518 WO2004012733A2 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Publications (2)

Publication Number Publication Date
DE60316297D1 true DE60316297D1 (de) 2007-10-25
DE60316297T2 DE60316297T2 (de) 2008-06-19

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316297T Expired - Lifetime DE60316297T2 (de) 2002-08-01 2003-07-31 Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind

Country Status (17)

Country Link
US (1) US20060058395A1 (de)
EP (1) EP1526851B1 (de)
JP (1) JP2005537336A (de)
KR (1) KR20050026091A (de)
CN (1) CN1671378A (de)
AT (1) ATE372770T1 (de)
AU (1) AU2003260280A1 (de)
BR (1) BR0312929A (de)
CA (1) CA2493253A1 (de)
DE (1) DE60316297T2 (de)
IL (1) IL166040A0 (de)
IS (1) IS7723A (de)
MX (1) MXPA05001235A (de)
NO (1) NO20051074L (de)
NZ (1) NZ537809A (de)
PL (1) PL375318A1 (de)
WO (1) WO2004012733A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004017175D1 (de) 2003-06-17 2008-11-27 Neurosearch As Diphenylurea-derivative und ihre verwendung als chloridkanalblocker
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
WO2006085302A2 (en) * 2005-02-08 2006-08-17 Bmz Diagnosis (2004) Ltd. Composition for treatment of skin disorders
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
KR20080027890A (ko) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20110110958A1 (en) * 2007-09-11 2011-05-12 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
EP3458052B1 (de) 2016-05-17 2019-11-06 Scandion Oncology A/S Kombinationsbehandlung für krebs
EP3846802A1 (de) * 2018-09-06 2021-07-14 Scandion Oncology A/S Harnstoffderivate zur verwendung bei der behandlung von personen mit erhöhter expression und/oder aktivität von srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (de) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 rezeptor antagonisten
WO1998047879A1 (en) * 1997-04-22 1998-10-29 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
WO1999032436A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
AP2001002103A0 (en) * 1998-10-22 2001-03-31 Neurosearch As Substituted phenyl derivatives, their preparation and use.
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos

Also Published As

Publication number Publication date
IL166040A0 (en) 2006-01-15
WO2004012733A9 (en) 2005-03-10
DE60316297T2 (de) 2008-06-19
ATE372770T1 (de) 2007-09-15
US20060058395A1 (en) 2006-03-16
CA2493253A1 (en) 2004-02-12
EP1526851A2 (de) 2005-05-04
IS7723A (is) 2005-03-01
NZ537809A (en) 2007-05-31
MXPA05001235A (es) 2005-06-08
CN1671378A (zh) 2005-09-21
EP1526851B1 (de) 2007-09-12
WO2004012733A2 (en) 2004-02-12
WO2004012733A3 (en) 2004-03-18
BR0312929A (pt) 2005-07-12
NO20051074L (no) 2005-04-29
AU2003260280A1 (en) 2004-02-23
PL375318A1 (en) 2005-11-28
JP2005537336A (ja) 2005-12-08
KR20050026091A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
IS7723A (is) Efnasambönd sem eru gagnleg til meðhöndlunar á sjúkdómum sem svara meðferð sem bælir æðamyndun
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
GB0222495D0 (en) Compounds
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60228103D1 (de) Chemische verbindungen
ATE325125T1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
DE602004015269D1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
UA85559C2 (en) Aminobenzophenone compounds
BR0312446A (pt) 2-heteroaril carboxamidas
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
ECSP056057A (es) Compuestos de benzo[1,2,5]tiadiazole
ATE418550T1 (de) 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen
DE60222286D1 (de) Verfahren zur erhöhung des testosteronspiegels
DE60228295D1 (de) Chemische verbindungen
EP1597234A4 (de) Neue verbindungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
ATE360062T1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition